T1	Participants 86 117	children with autistic disorder
T2	Participants 819 1095	male and female outpatients aged 5-12 years with a diagnosis of autistic disorder based on the DSM-IV-TR criteria and a score of ≥12 on the Aberrant Behavior Checklist-Community (ABC-C) irritability subscale who had discontinued other medications because of a lack of efficacy
T3	Participants 1661 1694	Forty-nine patients were enrolled
T4	Participants 1713 1785	forty children completed the trial (dropouts: placebo = 4, riluzole = 5)
